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Abstract
Background: Ewing’s sarcomas are aggressive musculoskeletal tumors occurring most frequently in the long and
flat bones as a solitary lesion mostly during the teen-age years of life. With current treatments, significant number
of patients relapse and survival is poor for those with metastatic disease. As part of novel target discovery in
Ewing’s sarcoma, we applied RNAi mediated phenotypic profiling to identify kinase targets involved in growth and
survival of Ewing’s sarcoma cells.
Results: Four Ewing’s sarcoma cell lines TC-32, TC-71, SK-ES-1 and RD-ES were tested in high throughput-RNAi
screens using a siRNA library targeting 572 kinases. Knockdown of 25 siRNAs reduced the growth of all four
Ewing’s sarcoma cell lines in replicate screens. Of these, 16 siRNA were specific and reduced proliferation of
Ewing’s sarcoma cells as compared to normal fibroblasts. Secondary validation and preliminary mechanistic studies
highlighted the kinases STK10 and TNK2 as having important roles in growth and survival of Ewing’s sarcoma cells.
Furthermore, knockdown of STK10 and TNK2 by siRNA showed increased apoptosis.
Conclusion: In summary, RNAi-based phenotypic profiling proved to be a powerful gene target discovery strategy,
leading to successful identification and validation of STK10 and TNK2 as two novel potential therapeutic targets for
Ewing’s sarcoma.
Introduction
Ewing’s sarcoma represents approximately three percent
of pediatric cancers and is the second most common
bone malignancy in children and adolescents [1,2]. It is
an aggressive cancer with a tendency to recur following
resection and it metastasizes to the lung, bone and bone
marrow. Ewing’s sarcomas harbor unique chromosomal
translocations that give rise to fusion genes that act as
oncoproteins [3]. Rearrangement of the EWS gene on
chromosome 22q12 with an ETS gene family member is
the underlying molecular genetic abnormality for
Ewing’s sarcoma. The most common translocation
involves the genes EWS and Friend Leukemia Integra-
tion Site 1 (FLI1). This translocation can be further sub-
divided into two separate types, Type I and Type II,
with Type I resulting from the translocation fusing EWS
exon 7 to FLI-1 exon 6 and Type II resulting from the
fusion of EWS exon 7 to FLI1 exon 5. The newly
formed EWS-FLI1 fusion protein is a transcription
factor that can then lead to aberrant transcription [4].
Morphologically, Ewing’s sarcoma is composed of
small round cells with high nuclear to cytoplasmic ratio
and cells from more than 90% of patients express the
adhesion receptor CD99 [5,6]. Disease management for
patients with localized disease has substantially
improved but the prognosis for those with metastatic or
recurrent disease has changed very little over the past
three decades. Currently, Ewing’s sarcoma patients are
treated with a combination of surgery, radiation and
chemotherapy [7]. Five-year event free survival for
patients with metastatic disease is only 20% and curative
therapy does not exist for patients whose disease recurs
rapidly following therapy for localized disease [7,8].
Recently, expression of several individual genes has been
linked to the development and progression of the dis-
ease, but so far there has been no comprehensive sys-
tematic study undertaken to identify functionally
relevant genes in Ewing’s sarcoma [9-13]. The genomic
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tool for accurate diagnosis. In addition, these common
genetic abnormalities could serve in identifying specific
genetic vulnerabilities, which would be useful in devel-
opment of targeted therapeutics for this disease.
In order to identify novel therapeutic targets for Ewing’s
sarcoma, we employed a functional genomics approach
based on high-throughput RNA interference (HT-RNAi),
which is also known as “loss-of-function” screening. The
b a s i so ft h i st e c h n o l o g yi sR N Ai n t e r f e r e n c e( R N A i ) ,a
robust method of post-transcriptional silencing of genes
using double-stranded RNA in the form of either siRNA
(short interfering RNA) or shRNA (short hairpin RNA)
with sequence homology driven specificity [14]. Large-
scale libraries of siRNA and shRNA have been used to
identify genes involved in many biological functions
[15-19]. We utilized a siRNA library targeting human
kinases to identify single siRNA kinase targets for Ewing’s
sarcoma cells. The availability of four Ewing’s sarcoma cell
lines that transfect well and are amenable to high through-
put screening enables us to identify essential kinase that
regulate growth of Ewing’s sarcoma cells. Numerous small
molecule kinase inhibitors to various different targets are
fairly well developed and rapid translation of our results
into the clinic is a real prospect from such screens. Results
from HT-RNAi screening of kinases identified seventeen
specific siRNAs (corresponding to sixteen genes) that lead
to reduced growth and proliferation of Ewing’ss a r c o m a
cells. We showed that two kinases, STK10 and TNK2, are
important in survival of Ewing’s sarcoma cells and repre-
sent potential therapeutic targets for future drug develop-
ment in this disease.
Materials and methods
Cell Culture
The human Ewing’s sarcoma cell lines TC-32 and TC-
7 1w e r eak i n dg i f tf r o mD r .J a v e dK h a n( P e d i a t r i c
Oncology Branch, National Cancer Institute, Gaithers-
b u r g ,M D ) .T h eE w i n g ’s sarcoma cell lines RD-ES and
SK-ES-1 were obtained from ATCC (Manassas, VA).
The human normal fibroblast cell line GM05659 was
obtained from the Coriell Institute (Camden, NJ). TC-
32, TC-71, and RD-ES cell lines were grown in RPMI,
supplemented with 10% FBS, 2 mM L-glutamine, 100
IU/ml penicillin G, and 100 μg/ml streptomycin. SK-ES-
1 cells were grown in McCoy’s 5A media supplemented
with 15% FBS, 2 mM L-glutamine, 100 IU/ml penicillin
G, and 100 μg/ml streptomycin. The normal human
fibroblast cell line GM05659 was grown in Minimum
Essentials Media (MEM) with 10% FBS and 2 mM L-
glutamine, 100 IU/ml penicillin G, and 100 μg/ml
streptomycin. All media reagents were obtained from
Invitrogen (Carlsbad, CA). The cell lines were routinely
maintained at 37°C in a humidified 5% CO2 atmosphere.
Reagents
The validated kinase siRNA library version 1.0 was
o b t a i n e df r o mQ i a g e n( V a l e n c ia, CA). Short interfering
RNAs targeting TNK2, STK10, PLK1 and non-silencing
control were also obtained from Qiagen (Valencia, CA).
The cationic lipid transfection reagent Lipofectamine
RNAiMAX was obtained from Invitrogen.
High Throughput RNAi Screening
High-Throughput RNAi (HT-RNAi) was performed
using the validated kinase siRNA library version 1. This
library includes siRNAs to 572 kinases with two siRNAs
per gene. Stock siRNA was diluted in siRNA buffer
(Qiagen) and 9.3 ng of siRNA was printed onto white
Corning 384-well plates (Fisher Scientific; Pittsburgh,
PA). HT-RNAi was done by reverse transfection of cells
as described previously [17]. Briefly, diluted Lipofecta-
mine RNAiMAX reagent (Invitrogen) in OptiMEM
(Invitrogen) was added to the wells and allowed to com-
plex with siRNA for 30 min at room temperature.
Ewing’s sarcoma cells were resuspended in growth
media without antibiotics at a final concentration of 750
cells/well for TC-32 and TC-71 or 1000 cells/well for
SK-ES-1, RD-ES and GM05659. Plates were incubated
at 37°C with 5% CO2. After 96 hours total cell number
was determined by the addition of Cell Titer Glo (Pro-
mega, Madison, WI) and relative luminescence units
(RLU) were measured using an EnVision plate reader
(Perkin-Elmer, Wellesley, MA). Raw RLU data was used
to calculate viability relative to control wells.
Screening Data Analysis
The screening data was normalized using the standard
Z-score method by correcting the raw data for plate row
variation, and then normalizing and pooling data from
all assay plates. The assumption is that the majority of
the siRNAs are non-hits and the null distribution is nor-
mal [20]. The criteria for identification of potential hits
used a Z-score cutoff of less than -1.65, which corre-
sponded to a p-value of 0.05, in both screens for each
cell line.
Quantitative real-time PCR
Cells were transfected with 16 nM of TNK2 and STK10
siRNA or non-silencing siRNAs in 6 well plates by
reverse transfection as described above. Cells were trea-
ted with siRNA for 48 hours and RNA was extracted
using standard procedures. qRT-PCR using Taqman
probes (Applied Biosystems, Carlsbad, CA, USA) was
performed as described previously [17]. For all experi-
ments, GAPDH gene was used as an internal control.
The relative quantification was given by the Ct values,
determined for triplicate reactions for test and reference
samples for each target and for the internal control gene
Arora et al. Molecular Cancer 2010, 9:218
http://www.molecular-cancer.com/content/9/1/218
Page 2 of 11(GAPDH). Relative expression level was determined as
2
-ΔΔCt,w h e r eΔΔCt = ΔCt (target sample) - ΔCt (refer-
ence sample).
Label-free Impedance Measurement of Cell Growth
The principle of impedance measurement for monitor-
ing cellular proliferation has been previously described
by Solly et al. [21]. Briefly, siRNA (against TNK2 and
STK10) was introduced into TC-71 cells by reverse
transfection of 4,000 cells/well using RNAiMAX in tri-
plicate wells of an ACEA 96X E-Plate (ACEA Bio-
sciences; San Diego, CA). The attachment, spreading
and proliferation of cells were continually monitored
every hour up to 150 hours, and changes in impedance
were acquired with the real time cell electronic sensing
(RT-CES) system (ACEA Biosciences). Cell growth was
determined by plotting cell index measurements versus
time.
In Vitro High Content Apoptotic Assay
To assess apoptosis within the cell population, TC-71
cells were seeded into 384-well plates and were treated
with siRNAs for the specified time and conditions
described above. Cells were incubated with 10 μlo fa
prepared solution containing 1X annexin V binding buf-
fer (BD Biosciences), annexin V-FITC (BD Biosciences),
Ethidium homodimer (EthD; Invitrogen), and Hoechst
33258 (Sigma Aldrich) for 20 minutes at 37°C. Images
were captured using the IN Cell Analyzer 3000 (GE
Healthcare) and apoptotic and dead cells were detected
using the IN Cell Developer Toolbox software. Nuclear
staining (Hoechst) was used to identify and quantify
total cell number. An image field was captured from
each replicated well and cells from three wells were
totaled and analyzed. Total number of cells labeled with
annexin V was compared to the total number of cells as
determined by Hoechst staining and the data was
expressed as a percentage of Annexin V stained cells.
Results
RNAi screening for the identification of vulnerable
“Achilles Heel” targets in Ewing’s sarcoma cell lines
In order to identify genes that modulate the growth and
survival properties of Ewing’ s a r c o m ac e l l s ,w ep e r -
formed loss-of-function screening using high throughput
RNAi (HT-RNAi) on four Ewing’s sarcoma cell lines.
We chose two Type I Ewing’s sarcoma cell lines (TC-32
and TC-71) and two Type II Ewing’s sarcoma cell lines
(RD-ES and SK-ES-1) for the HT-RNAi screening. A
robust HT-RNAi assay was developed and optimized
that allowed for high efficiency siRNA transfection of all
four Ewing’s sarcoma cell lines by cationic lipids in 384-
well plates (see Additional file 1: Figure S1). The HT-
RNAi screen involved transfecting the Ewing’s sarcoma
cells with siRNA from a validated siRNA library target-
ing 572 kinases. Ninety-six hours post transfection, cell
viability was assessed using a luminescence-based cell
viability assay and the data was normalized and analyzed
using Z-score method as described in Materials and
Methods [20]. Duplicate runs of the HT-RNAi screens
were conducted for each cell line and results are shown
as dot plots of the Z-score values (Figure 1). Significant
siRNA hits were classified as being 1.65 S.D. from the
median. Z-score values for all individual siRNAs for the
kinase screens are listed in the Additional file 2.
Comparison of the Z-score values for each individual
cell line screen shows very good correlation between the
duplicate screens. Similar HT-RNAi screens were per-
formed using normal human fibroblast cell line,
GM05659 (data not shown), for comparison to Ewing’s
sarcoma cell line data. A significant similarity between
the four Ewing’s sarcoma cell lines was observed when
compared to the normal fibroblast cell line GM05659 as
shown using a heat map plot (Figure 2A) and dendro-
gram (Figure 2B). These data show the robustness of
the phenotypic profiling differentiating Ewing’s sarcoma
cells from fibroblasts as well as two closely related sub-
types of Ewing’s sarcoma cell lines. The number of sig-
nificant hits for each Ewing’s sarcoma cell line and
overlapping hits are shown in a Venn diagram (Figure
2C) showing that silencing of 25 siRNAs were signifi-
cant across all four cell lines. Comparison of the over-
lapping Ewing’s sarcoma hits with the normal fibroblast
cell line showed that 17 siRNAs (corresponding to 16
genes) are specific for the Ewing’s sarcoma cells. Heat
map of the Z-scores shows specificity of these 16 siRNA
for decreasing cell number in Ewing’s sarcoma cells only
as opposed to a global lethal siRNA targeting PLK1
(polo like kinase 1) that also reduces proliferation of
normal fibroblast cells (Figure 2D). Of the 16 significant
gene hits that modulated the growth and proliferation of
Ewing’s sarcoma cell lines, two genes STK10 (serine
threonine kinase 10) and, TNK2 (tyrosine kinase, non-
receptor, 2) were prioritized for further confirmation
since both siRNAs targeting these genes were hits across
all four Ewing’s sarcoma cell lines (Figure 1). Confirma-
tion also included siRNA to PLK1 as a general lethal
positive control gene for comparison.
Confirmation of the effects of STK10, TNK2 and PLK1
silencing on growth and survival of Ewing’s sarcoma cells
We confirmed the effects of silencing of STK10, TNK2,
and PLK1 on growth and survival of Ewing’s sarcoma
cells by repeating the cell based assay in 384-well plates
using a different lot of siRNA having the same
sequences as the kinase library siRNA. Silencing of
STK10, TNK2 and PLK1 by both siRNA sequences
inhibited cell growth in the four Ewing’s sarcoma cell
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against STK10 and TNK2 showed significant reduction
in cell growth in both TC-32 and TC-71 cells. The
effect of STK10 and TNK2 knockdown on cell growth
was very similar to the effect of PLK1 knockdown in
these cells (Figure 3B). We next conducted the real-time
kinetic analysis to determine the effect of STK10 and
TNK2 siRNA treatment on Ewing’s cancer cells using
label-free impedance growth assays (Figure 4). The
impedance analysis showed that the treatment of TC-71
cells with STK10 and TNK2 siRNA resulted in a very
potent and sustained decrease in cell number compared
to non-silencing siRNA treatment (Figure 4). To
demonstrate the silencing efficiency of the siRNAs tar-
geting TNK2 and STK10, TC-71 cells were transfected
with either the specific siRNAs or non-silencing siRNA
and incubated at 37°C for 48 hours. qRT-PCR was per-
formed using Taqman probes for both genes and
GAPDH was used as an internal control in both the
experiments. Fold change was calculated using the Delta
Delta Ct method and the results showed that at least
70% knockdown was observed using specific siRNAs
against STK10 and TNK2 (Insets in Figure 4). Further-
more, treatment of TC-32 cells with siRNA targeting
STK10 and TNK2 showed decrease in proteins levels
compared to untreated cells or non-silencing siRNA
treated cells (see Additional file 1: Figure S2). These
results confirm that the siRNAs targeting STK10 and
TNK2 led to specific gene knockdown in our
experiments.
Gene Silencing of STK10 and TNK2 induces apoptosis
We next examined the effect of STK10 and TNK2
siRNA treatment on the induction of apoptosis in TC-
71 cells using a high content, image based analysis of
annexin V staining. Image based analysis showed that
treatment of TC-71 cells with siRNA targeting TNK2
and STK10 increase annexin V staining compared to
cells treated with negative control non-silencing siRNA
( F i g u r e5 ) .T h e s ed a t ai n d i c a t et h a tt h ek n o c k d o w no f
STK10 and TNK2 induce apoptosis of Ewing’s sarcoma
cells. Representative images from the cells treated with
TNK2_6 siRNA show various apoptotic bodies asso-
ciated with TNK2 silencing (Figure 5B).
Discussion
Ewing’s sarcoma is a disease that appears to be etiologi-
cally driven by a few primary genetic abnormalities
involving a fusion of an EWS family member with a
transcription factor, of which the commonly fused
Figure 1 RNAi screening of Ewing’s sarcoma cell lines.E w i n g ’s sarcoma cell lines TC-32, TC-71, SK-ES-1 and RD-ES were transfected with
siRNA targeting 572 kinases and assayed for cell viability at 96 hr as described in Material and Methods. Assays were done in duplicate and Z-
score values for each siRNA treatment was plotted. Each circle represents data for one siRNA and the two colors represent data from the
duplicate runs for the same cell lines. The dotted red line indicates the cut off for the significant Z score (-1.65 SD). The darkened circles
correspond to the data for chosen hits STK10 and TNK2.
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tumors offer a relatively homogenous model system for
the identification of specific contextual vulnerabilities
that could be targeted with novel therapeutic strategies.
An improved understanding of the molecular biology of
Ewing’s sarcoma and the underlying genetic context has
led to clinical trials of several novel therapies specifically
designed to thwart critical pathways responsible for this
malignancy [22]. Understanding how and when to inte-
grate such therapies into clinical practice, although chal-
lenging, may lead to a paradigm shift towards more
personalized therapy.
In recent years, there have been various independent
studies looking at several different kinases and their role
in sarcoma cell survival as well as their potential to be
developed into specific therapeutics. In a study by
Andersson et al. it was shown that proliferation of
Ewing sarcoma cell lines is suppressed by the receptor
tyrosine kinase inhibitors gefitinib and vandetanib [23].
Similarly, anti-tumor activity of GSK1904529A, a small-
molecule inhibitor of the insulin-like growth factor-I
receptor tyrosine kinase was reported in Ewing’ss a r -
coma [24]. In some other studies, kinases such as JNK,
TOPK, AURKA, AURKB and LYN have all been studied
in Ewing’s sarcoma [25-27].
We undertook this study with the goal of identifying
kinases that can be targeted to modulate Ewing’ss a r -
coma cell growth and survival. By conducting phenotype
Figure 2 Phenotypic profiling of kinases. (A) Heat map showing the correlation between each independent RNAi screen for the four Ewing’s
sarcoma cell lines and the normal fibroblast cell line GM05659; Z-scores were used for the generation of the Heat Map. (B) Dendogram showing
the correlation coefficients between all the independent siRNA screening runs; Z-scores were used for calculating the correlation coefficients. (C)
Venn Diagram on the left depicts the number of significant siRNA hits for each cell line chosen based on significant Z-scores from both the
independent runs for every Ewing’s sarcoma cell line. Venn diagram on the right shows the overlap of significant siRNA hits between the normal
fibroblast cell line and genes significant across all four Ewing’s sarcoma cell lines (D) Heat map of Z-score values for the 17 siRNA hits and a
PLK1 siRNA. This Heat map was generated using CIMminer http://discover.nci.nih.gov/.
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32, TC-71, SK-ES1 and RD-ES cells using two siRNAs per gene. Ewing’s sarcoma cells were transfected with siRNA by reverse transfection in 384-
well microtiter plates and grown for 96 hrs. Each siRNA treatment was performed in quadruplicate wells. Cell number was assessed as described
in Material and Methods. Treatment of Ewing’s sarcoma cells with siRNA targeting STK10, TNK2 and PLK1 significantly decreased cell viability (p <
0.0001) compared to non-silencing siRNA controls. Data is representative of three independent experiments. (B) Representative images of TC-32
and TC-71 Ewing’s sarcoma cells treated with siRNA shows decreased cell number and increased cellular toxicity. Bar represents 100 μm.
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we were able to obtain a better global understanding of
contextual vulnerabilities in Ewing’s sarcoma. We devel-
oped robust siRNA-screening assays for four Ewing’s
s a r c o m ac e l ll i n e s ,T C - 3 2 ,T C - 7 1 ,S K - E S - 1a n dR D - E S
and performed HT-RNAi screens to generate data on
the growth inhibiting effect of targeting 572 kinases
(Figure 1). These data were compared to a data set from
the normal fibroblast cell line GM05659 and showed
stronger correlation between the Ewing’s cell lines ver-
sus the normal fibroblast cells. This observation demon-
strated that the two different types of Ewing’s sarcoma
cell lines could be grouped based on phenotypic
profiling. Gene lists were compiled to identify growth-
inhibiting targets in Ewing’s sarcoma cells (see Addi-
tional file 2 and Table 1). We identified 25 siRNAs that
were “hits” across all four Ewing’s sarcoma cell lines and
17 of these siRNAs were unique to the Ewing’ss a r c o m a
cell lines when compared with the normal fibroblast cell
line data (Figure 2C and 2D). These 17 siRNAs repre-
sent 16 genes since both the siRNAs targeting STK10
were on the list. Several of these genes “hits” have
already been reported to have association with Ewing’s
sarcoma. For example, AKT1, is a downstream kinase of
phosphoinositide 3-OH kinase and has been shown to
prevent apoptosis and support survival of many cell
Figure 4 STK10 and TNK2 knockdown leads to decreased cell viability of Ewing’s sarcoma cells. TC-71 cells were transfected with siRNAs
against STK10, TNK2 or non-silencing control. Growth was assessed by impedance measurements at 1-hour intervals and cell index was plotted
as a function of time. (A) Treatment of TC-71 cells with non-silencing siRNA or two different TNK2 siRNA showed reduced cell growth in cells
with TNK2 knockdown (B) Treatment of TC-71 cells with non-silencing siRNA or two different STK10 siRNA showed reduced cell growth in cells
with STK10 knockdown. Data is representative of three independent experiments. Confirmation of gene silencing was shown by qRT-PCR for (A
inset) STK10 and (B inset) TNK2. Each individual siRNA was reverse transfected into TC-71 cells and incubated at 37°C for 48 hours. RNA was
extracted 48 hours later and cDNA was prepared using random primers. qRT-PCR was done using specific TaqMan probes and all the results
were normalized to GAPDH expression.
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gene, MK-STYX is expressed in ESFT samples and was
shown to be a target of EWS-FLI1 by chromatin immu-
noprecipitation. MK-STYX encodes for a phosphatase-
dead dual specificity phosphatase-like protein implicated
in the regulation of MAP kinases [29]. The actual func-
tion of STYX proteins is not known but it is suggested
that they bind to phosphorylated kinases, thereby pre-
venting de-phosphorylation by active phosphatases keep-
ing the kinases in an active state [30]. Our results show
that MK-STYX knockdown reduces cell survival in
Ewing’s sarcoma cells. One other target NTRK3 is the
transcription factor component of common transloca-
tion fusion protein, ETV6-NTRK3, which occurs com-
monly in congenital (infantile) fibrosarcoma and cellular
mesoblastic nephroma [31].
Two kinase inhibitors in clinical trails for several dif-
ferent cancer types are gefitinib (targets EGFR) and van-
detinib (antagonist of VEGFR, EGFR and RET-tyrosine
kinase). In our screens, siRNAs to EGFR and RET-
kinases did not lead to significant reduction in prolifera-
tion and our siRNA library unfortunately did not
include VEGFR siRNAs. Additionally, IGF1 and IGF1R
were not on our siRNA library but we tested siRNAs for
IGF1R, which showed inhibition of cell growth in all the
four cell lines (see Additional file 1: Figure S3). Interest-
ingly, siRNAs against AURKB led to significant reduc-
tion in growth of type II cell lines (SK-ES-1 and RD-ES)
while the type I cell lines (TC-32, TC-71 and the normal
fibroblast cells lines remained unaffected. The siRNA
against LYN, TOPK and JNK did not affect Ewing’ss a r -
coma cell proliferation while siRNA against AURKA had
only a marginal effect.
The list of hits from our siRNA phenotypic profiling
of Ewing’s sarcoma cells indicates potential targets that
could be exploited clinically. Over the last years, several
inhibitors against targets in Table 1 have been
Figure 5 STK10 and TNK2 knockdown induces apoptosis in Ewing’s sarcoma cells. TC-71 cells were transfected with siRNAs against STK10,
TNK2 or non-silencing control. (A) STK10 and TNK2 knockdown by siRNA induces apoptosis in Ewing’s sarcoma cell lines. Bar graph showing the
increase in annexin V staining in Ewing’s sarcoma cells treated with siRNA targeting STK10 and TNK2 compared to non-silencing control siRNA.
Number of cells labeled with annexin V over total number of cells as determined by Hoechst staining from three image fields is shown above
the bar for each siRNA treatment. (B) Representative image showing Hoechst stained nuclei of TC-71 cells treated 72 hours with STK_6 siRNA
and corresponding Annexin V stained image.
Table 1 Gene targets identified by RNAi screening as






AKAP3 10566 A kinase (PRKA) anchor protein 3
AKT1 207 v-akt murine thymoma viral oncogene
homolog 1
CDK5R2 8941 cyclin-dependent kinase 5, regulatory
subunit 2
GRK4 2868 G protein-coupled receptor kinase 4
MAST1 22983 microtubule associated serine/threonine
kinase 1
MK-STYX 51657 STYXL1 serine/threonine/tyrosine
interacting-like 1
NEK3 4752 NIMA (never in mitosis gene a)-related
kinase 3
NEK9 91754 NIMA (never in mitosis gene a)- related
kinase 9
NTRK3 4916 neurotrophic tyrosine kinase, receptor, type
3
PIK3AP1 118788 phosphoinositide-3-kinase adaptor protein
1
PRKCA 5578 protein kinase C, alpha
PXK 54899 PX domain containing serine/threonine
kinase
STK10* 6793 serine/threonine kinase 10
STK11 6794 serine/threonine kinase 11
TAOK3 51347 TAO kinase 3
TNK2 10188 tyrosine kinase, non-receptor, 2
*Both the siRNAs for this gene showed significant growth inhibition.
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GSK690693 [33]) are in early phase clinical trials. An
inhibitor against PRKCA and other PKC isoforms,
PKC412, has been tested extensively in the clinic already
[34] and this could be a promising lead. Other PKC tar-
geting drugs are available as well, mostly for experimen-
tal purposes [35]. Additional targets may be worthwhile
exploring such as CDK5R2. There are no direct inhibi-
tors against CDK5R2, which is a regulatory subunit of
CDK5. However, we recently reported a Phase I clinical
study with a well tolerated oral multi-CDK inhibitor
that potently inhibits CDK5 [36]. Therefore, with an
increasing number of inhibitors becoming available, hit
lists from RNAi screens can directly inform translational
research and drug development.
In this study, we chose three genes STK10, TNK2 and
PLK1 for further validation studies as these genes were
prioritized by having significant Z-score values for both
siRNAs across all screens in the four Ewing’s sarcoma
cell lines. We confirmed that PLK1 knockdown led to
increased cell death, but did not appear to be specific to
Ewing’s sarcoma cells as it was also a significant “hit”
for normal fibroblasts (Figure 2D). Furthermore, PLK1
has been shown to be involved in cell death processes
for many other different types of cancers, including
rhabdomyosarcomas, osteosarcomas, hepatocellular car-
cinomas, esophageal carcinomas as well as hematologi-
cal malignancies and in this study we intended to focus
on novel targets for Ewing’s sarcoma [19,37-43].
The two other promising targets identified from this
RNAi screen were STK10 and TNK2. Our results clearly
showed that both these genes are involved in Ewing’s
sarcoma cell growth and survival and are anti-apoptotic
(Figures 3, 4, and 5). These results suggest that both
STK10 and TNK2 would be promising kinase targets for
therapeutic intervention in Ewing’s sarcoma. Recently,
several studies by Grueneberg and colleagues have
shown that various different types of cancer cells depend
on different and specific kinases for cell survival. They
successfully studied “kinomes” in cervical, lung and
renal cells. On browsing their target gene lists we did
not see STK10 and TNK2 as “hits” in any of their
screens, which also points to the fact that these two tar-
gets might be specific to Ewing’s sarcoma [44-47].
Mining of gene-expression data indicate that both
STK10 and TNK2 are not highly over-expressed in
Ewing’s sarcoma [48], hence over-expression of these
genes may not be a driver for their functional specificity
in this disease. STK10 belongs to the Ste20 family of
serine/threonine kinases plays an important role in
numerous cellular functionss u c ha sg r o w t h ,a p o p t o s i s ,
and morphogenesis [49,50]. This protein has not been
associated with cancer and most of the previous reports
have studied its expression in T-cells, lymphocytes and
hematopoetic tissues [51,52]. STK10 is a human homo-
log of murine Lok, a serine/threonine kinase highly
expressed in lymphocytes. STK10 can associate with
PLK1 in cells and can phosphorylate PLK1 in vitro [50]
and engineered NIH-3T3 cell lines that over-express a
dominant negative version of STK10 display an altered
cell cycle phenotype characterized by increased DNA
content, which raises the possibility that expression of a
dominant negative STK10 may impinge upon PLK1
function in vivo and it has previously been shown that
unregulated expression of PLK1 can result in a variety
of nuclear defects. These observations are in accordance
with our data, wherein we show that STK10 knockdown
leads to increased apoptosis and cell death of Ewing’s
sarcoma cells. Our results also show that the normal
fibroblast cells do not depend on STK10, as there is
minimal cell death after STK10 knockdown in these
cells. Although, there have been no previous reports dis-
cussing the role of STK10 in sarcomas, our results
clearly demonstrate an important role for STK10 in
growth and survival of Ewing’s sarcoma cells.
Next, we validated the results for TNK2 knockdown
and similar to STK10, TNK2 also led to increased cell
death and apoptosis. TNK2, also known as ACK1 binds
specifically to Cdc42 (a member of the Rho family of
GTPases). Cdc42, like other Rho family members, is
involved in transducing oncogenic signals from Ras to
develop a transformation phenotype in mammalian cells.
Pathway analysis conferred that TNK2 has been corre-
lated with several different growth signaling pathways
and is known to regulate some of the most important
growth regulators in cancer cells (see Additional file 1:
Figure S4). TNK2 has been shown to be involved in cell
migration and induction of metastasis in transformed
cells [53]. TNK2 also activates JNK and p38 mediated
signaling pathways, which lead to induction of gene
expression [54,55]. Recently, Howlin et al have shown
that TNK2 preserves epidermal growth factor receptor
expression on the cell surface and enhances migration
and invasion of human breast cancer cells, but TNK2
did not affect apoptosis of the cells [56]. This is contrary
to our observation in Ewing’s sarcoma cells, wherein we
showed that TNK2 knockdown is indeed responsible for
causing cell death through apoptosis. These differences
in TNK2 function might be attributed to the different
cell types under investigation. Nonetheless, it is interest-
ing to note that all the functions attributed to TNK2 so
f a rp o i n tt ot h ef a c tt h a tt h i sg e n em i g h tp l a yas i g n i f i -
cant role in the development and progression of cancer.
Conclusions
In conclusion, this is the first study demonstrating the
use of phenotypic profiling and high throughput RNAi
screening to identify novel kinase targets for Ewing’s
Arora et al. Molecular Cancer 2010, 9:218
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Page 9 of 11sarcoma. Using this powerful approach, we were able to
identify and validate two kinases, STK10 and TNK2,
which have the potential to be targets for disease speci-
fic therapeutics.
Additional material
Additional file 1: Supplementary Figures. File contains the following
figures: Figure S1. Transfection optimization data showing efficacy of the
selected transfection reagent and ratio on the four Ewing’s sarcoma cell
line; Figure S2. Confirmation of protein knockdown by siRNA; Figure S3.
Effect of IGF1R silencing on Ewing’s sarcoma cells; Figure S4. Interactions
of TNK2.
Additional file 2: Z-score values for kinase siRNA library screen of
Ewing’s sarcoma cells. Table showing the Z-score values of each siRNA
in the HT-RNAi screen using the kinase library.
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